Work

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

Year: 2017

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2017.08.001

Authors: Premal H. Thaker, William E. Brady, Heather A. Lankes, Kunle Odunsi, William H. Bradley, Kathleen N. Moore, Carolyn Y. Muller, Khursheed Anwer, Russell J. Schilder, Ronald D. Alvarez, Paula M. Fracasso

Institutions: Washington University in St. Louis, Alvin J. Siteman Cancer Center, Roswell Park Comprehensive Cancer Center, NRG Oncology, Medical College of Wisconsin, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Oklahoma, University of New Mexico, Celsion (United States), Thomas Jefferson University, University of Alabama at Birmingham, UAB Medicine, University of Virginia Cancer Center, University of Virginia

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: University of Alabama at Birmingham, Medical College of Wisconsin, NRG Oncology, University of Oklahoma Health Sciences Center, Health Sciences Center, University of New Mexico, National Cancer Institute

Awards: G1291646684, Washington University/ Siteman Cancer Center Lead Academic Site, G1950154987, G215985982, NRG Oncology Network Group Operations Center, G467764903, G5996839100, Lead Academic Participating Site for the Development and Conduct of NCTN Trials, G70736214, G7484487955, G8494369300

OpenAlex ID: W2743804580

FWCI: 4.598

Cites: 42

Cited by: 65

Related to: 10